Novo Nordisk A/S held its operating margin steady at 45.3% in the first nine months of the year as sales of non-insulin medicines increased and administrative costs remained flat. Group sales for the period were DKK 94.8 billion (€12.73 billion), up by 6% from a year-earlier on a reported basis, and by 7% at constant exchange rates.
